GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Net Cash per Share

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Net Cash per Share : $4.02 (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Inovio Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 was $4.02.

The historical rank and industry rank for Inovio Pharmaceuticals's Net Cash per Share or its related term are showing as below:

INO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.52   Med: 4.52   Max: 10.5
Current: 2.63

During the past 13 years, the highest Price-to-Net-Cash Ratio of Inovio Pharmaceuticals was 10.50. The lowest was 1.52. And the median was 4.52.

INO's Price-to-Net-Cash is ranked better than
62.51% of 867 companies
in the Biotechnology industry
Industry Median: 3.92 vs INO: 2.63

Inovio Pharmaceuticals Net Cash per Share Historical Data

The historical data trend for Inovio Pharmaceuticals's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Net Cash per Share Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.04 21.39 16.84 6.01 4.02

Inovio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.01 7.14 5.88 5.01 4.02

Competitive Comparison of Inovio Pharmaceuticals's Net Cash per Share

For the Biotechnology subindustry, Inovio Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Price-to-Net-Cash falls into.



Inovio Pharmaceuticals Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Inovio Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(145.294-53.602-0)/22.7931
=4.02

Inovio Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(145.294-53.602-0)/22.7931
=4.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inovio Pharmaceuticals  (NAS:INO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Inovio Pharmaceuticals Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Headlines

From GuruFocus

INOVIO Reports Inducement Grants Under Inducement Plan

By PRNewswire PRNewswire 06-01-2023